Neurocrine Biosciences | NBIX - Ebitda


Neurocrine Biosciences reported $246.7M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
AbbVie USD 4.34B 56M Jun/2025
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
Agios Pharmaceuticals USD -125.8M 20.45M Jun/2025
ALKERMES USD 121.55M 4.99M Sep/2025
Alnylam Pharmaceuticals USD 381.78M 362.95M Sep/2025
Amgen USD 5.91B 2.31B Sep/2025
Biogen USD 1.01B 456.5M Jun/2025
BioMarin Pharmaceutical USD 295.45M 49.49M Jun/2025
Cytokinetics USD -107.82M 45.51M Jun/2025
Dynavax Technologies USD 35.53M 10.9M Sep/2025
Exelixis USD 248.93M 28.02M Sep/2025
Gilead Sciences USD 4.03B 628M Sep/2025
Halozyme Therapeutics USD 248.25M 22.74M Sep/2025
Incyte USD 581.52M 358.87M Jun/2025
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
Neurocrine Biosciences USD 246.7M 93.8M Sep/2025
Pfizer USD 6.08B 351M Sep/2025
Prothena USD -39.53M 12.25M Sep/2025
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Repligen USD 35.93M 3.75M Sep/2025
Sarepta Therapeutics USD 126.42M 416.82M Jun/2025
Teva Pharmaceutical Industries USD 1.64B 243M Dec/2025
Ultragenyx Pharmaceutical USD -91.34M 35.09M Jun/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025